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Fig. 1. Colonoscopic examination 
revealed a transverse ulcer on 
the proximal portion of the as-
cending colon (A, arrow). This 
lesion disappeared after antitu-
berculosis treatment (B).
Abdominal tuberculosis is not a rare disease, but ob-
structive jaundice caused by tuberculosis (tuberculous 
lymphadenitis, tuberculous enlargement of the head of 
pancreas, and/or tuberculous stricture of the biliary 
tree) is rare. We recently experienced a case of ob-
structive jaundice as a result of paradoxical reaction 
of periportal tuberculous lymphadenopathy that was 
treated successfully with corticosteroid and biliary 
drainage. No similar cases have been reported pre-
viously.  (Gut and Liver 2009;3:338-342)
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INTRODUCTION
The paradoxical reaction (PR) in antituberculosis therapy 
is defined as the clinical or radiological deterioration of 
pre-existing lesions or new lesion formation in patients 
who were improved with initial treatment.
1 Most reported 
cases have complicated the treatment of cervical lymph 
node or cerebral disease and rarely reported in the ab-
dominal tuberculosis.
2-4 However, there is no reported 
case of obstructive jaundice as a result of PR of periportal 
tubercular lymphadenopathy. Therefore we report a case 
with biliary obstruction by enlarged lymph node which 
was successfully treated with corticosteroid and transient 
placement of a stent.
CASE REPORT
  A 23-year-old man visited our hospital due to chronic 
diarrhea and weight loss. He has no history of injection 
drug abuse or homosexual activity. The antibody test for Lee YJ, et al: A Case of Paradoxical Reaction in Abdominal Tuberculosis   339
Fig. 2. The pathology results of the endoscopic biopsy showing granulomatous inflammation (A, H&E stain, ×40: B, ×100).
Fig. 3. The second colonoscopic 
examination revealed white ulcer 
scar changes from the previous 
ulcerative lesion (A, arrow). 
However, a new protruding mass 
with a central ulcer was noted 
on the proximal ascending colon 
(B, arrowheads). Six months 
later, the ulcer lesion near the 
ileocecal valve was completely 
healed (C) and there were only 
white ulcer scar changes on the 
ascending colon (D).
human immunodeficiency virus was negative. Abdominal 
computerized tomography (CT) scan showed diffuse retic-
ularly-increased fat attenuation on the omentum, peri-
toneal thickening and multiple heterogeneously enhancing 
lymph nodes in portocaval, mesenteric root and ileocolic 
chain. The distal ileum and proximal ascending colonic 
walls were mildly thickened. The colonoscopic examina-
tion revealed transverse ulcers on the ileocecal valve and 340   Gut and Liver, Vol. 3, No. 4, December 2009
Fig. 4. An enlarged lymph node was found in the periportal area (A, arrow). A newly developed, enhancing 2-cm mass lesion was 
noted on the proximal ascending colon (B, arrowhead).
Fig. 5. Endoscopic retrograde cholangiopancreatography revealed an extrinsic compression of the midportion of the common bile 
duct by the extrinsic mass (A, arrow). A 7-cm polyethylene stent was inserted successfully (B, arrowheads). The previously 
narrowed common bile duct was improved after the treatment (C).
ascending colon (Fig. 1). The endoscopic biopsy demon-
strated granulomatous inflammation (Fig. 2). Though the 
results of tuberculosis polymerase chain reaction (PCR) 
and acid fast bacilli (AFB) stain were negative, empirical 
antituberculous chemotherapy including isoniazide, ri-
fampin, ethambutol, and pyrazinamide was started under 
the tentative diagnosis of tuberculosis colitis, peritonitis 
and lymphadenitis. 
  T h r e e  m o n t h s  l a t e r ,  t h e  s e c o n d  c o l o n o s c o p i c  e x a m i n a -
tion showed whitish ulcer scar on the ileocecal valve and 
newly developed protruding mass lesion with central shal-
low ulcer on the ascending colon (Fig. 3A, B). The fol-
low-up abdominal CT revealed improvement of lymphade-
nopathies in the portocaval, mesenteric root and ileocolic 
chain. However, lymph node enlargements showing ne-
crotic foci located at the periportal area were aggravated 
and about 2 cm sized newly enhancing mass was newly 
noticed in the ascending colon (Fig. 4B). The biopsy from 
newly developed mass demonstrated granuloma with neg-
ative AFB stain and negative tuberculosis PCR result. Lee YJ, et al: A Case of Paradoxical Reaction in Abdominal Tuberculosis   341
Because the clinical symptoms and the initial endoscopic 
finding were much improved with antituberculosis medi-
cation, we considered those changes as tuberculoma re-
lated to PR in antituberculosis treatment. Hence, oral pre-
dnisolone (30 mg/d) was added for 1 month and tapered. 
However, the patient was re-admitted due to epigastric 
pain and jaundice two weeks after the cessation of the 
corticosteroid therapy. The laboratory results were as fol-
lows: aspartate transaminase 171 IU/L (1-39 IU/L), ala-
nine tranaminase 181 IU/L (1-39 IU/L), Alkaline phopha-
tase 249 IU/L (25-100 IU/L), and total bilirubin 2.7 
mg/dL (0.1-1.2 mg/dL). Follow-up CT scan revealed more 
enlarged necrotic lymphadenopathy at the periportal area 
and dilatation of the common bile duct (Fig. 4A). 
Endoscopic retrograde cholangiopancreatography (ERCP) 
was performed and an extrinsic compression of mid por-
tion of the common bile duct by the extrinsic mass lesion 
was demonstrated (Fig. 5A). For reliving the obstruction, 
the patient underwent the endoscopic retrograde biliary 
drainage with a single 7 cm-sized 10 Fr polyethylene 
stent with a total length of 7 cm and additional oral cor-
ticosteroid therapy was re-started for 1 month and ta-
pered (Fig. 5B). Six months later, he eventually recovered 
with antituberculosis medication. Follow-up colonoscopic 
examination and CT scan showed disappearance of pre-
vious lesions (Fig. 3B, C). Because the follow up ERCP 
revealed marked improvement of the previously ob-
structed biliary tree, the previously inserted common bile 
duct stent was removed. The cholangiogram after removal 
of the stent was nearly normalized (Fig. 5C). 
DISCUSSION
  PR during antituberculosis therapy is not a rare pheno-
menon.
2,3 I t  i s  i d e n t i f i e d  i n  6 - 2 5 %  o f  p a t i e n t s  r e c e i v i n g  
antituberculosis therapy.
2-6 This phenomenon usually in-
volves new or increasing enlargement of peripheral lymph 
nodes, cerebral tuberculomas, pulmonary infiltrates, or 
pleural disease. However, it is rare in the abdominal 
tuberculosis.
2-4 PRs most frequently occur during the first 
few months of antituberculosis treatment and usually re-
solve with continued therapy.
3,7 B i o p s i e s  o f  a f f e c t e d  t i s -
sues usually show granulomatous inflammation with neg-
ative AFB smears and cultures.
8
  The mechanisms of PR have been understood as de-
crease in suppressor mechanisms related to active tuber-
culosis infection, strengthening of delayed hypersensitivity 
response of the host, and heavy exposure to mycobacte-
rial antigens following bactericidal tuberculosis chemo-
therapy.
7,9 Cheng et al.
3 reported that the risk factors for 
development of PR during antituberculosis therapy in 
HIV-negative patients are extra-pulmonary tuberculosis, 
with or without pulmonary involvement and lower base-
line lymphocyte counts.
  However, PR during antituberculosis therapy remains a 
diagnostic dilemma. The diagnosis can only be confirmed 
after exclusion of other differential diagnosis such as sec-
ondary infections, inadequate therapy or drug resistance, 
poor compliance and a side effect of antituberculosis 
therapy. In our case, we considered the aggravated lym-
phadenopathies and newly developed mass lesion on the 
ascending colon as PR because his clinical symptoms 
were disappeared and other lesions found on the second 
colonoscopic examination were improved with antituber-
culosis medications. Hence, the antituberculosis therapy 
was continued and additional corticosteroid treatment 
was tried. The obstruction of the common bile duct by 
the enlarged periportal lymph node was successfully treat-
ed with additional corticosteroid therapy and biliary 
stenting.
  While PRs are usually self-limited, respiratory failure 
and death can be occurred.
10 Sometimes corticosteroid is 
used for relieving PR. The known advantage of cortico-
steroid therapy is reducing edema around enlarging intra-
cranial tuberculomas. However, it is unclear that the ad-
vantage of steroid therapy for lymph node tuberculosis.
7 
Some reported rapid recovery after the initiation of corti-
costeroid therapy.
5,11-13 The treatment resulted in clinical 
improvement in many cases in a median time of 3 days. 
Effective doses of the prednisolone ranged from 10 to 80 
mg daily. When corticosteroids were tapered gradually, 
PR recurred in one third of the patients after their 
discontinuation.
2,3 Most patients with relapsed PR res-
poned again to corticosteroid retreatment.
2 However, in 
other reports, continued deteriorations have been reported 
despite of corticosteroid treatment.
12 Furthermore, PRs 
have occurred in patients who were given corticosteroid 
from the outset of their antituberculosis treatment and 
another report has provided PRs that resolved without 
corticosteroid treatment.
14,15
  Obstructive jaundice caused by tuberculosis is rare. It 
can be caused by tuberculous lymphadenitis,
16 tuber-
culosis of the pancreatic head,
17 biliary stricture after bili-
ary tuberculosis
18 or lymph node fistulation in the com-
mon bile duct.
19 There were no reported cases of ob-
structive jaundice related with tuberculous lymphadenitis, 
especially during antituberculosis therapy. In addition, 
most cases of periportal lymphadenitis were confirmed by 
diagnostic laparoscopy or surgical resection.
17,20 The main-
stay of treatment in bile duct stricture or extrinsic com-
p r e s s i o n  b y  t u b e r c u l o u s  l e s i o n  i s  t o  r e l i e v e  t h e  o b -
struction and to administer antituberculosis therapy. 342   Gut and Liver, Vol. 3, No. 4, December 2009
Surgical bypass for the relief of bile duct obstruction is 
often required.
21 Endoscopic stenting of the stricture has 
also been reported.
18,21,22 In our case, corticosteroid ther-
apy and biliary stent for 6 months successfully reduced 
the extrinsic compression by the enlarged lymph node. To 
our knowledge, there was no reported case of common 
bile duct obstruction by lymphadenopathy related to PR 
during antituberculosis therapy, which was treated by en-
doscopic stenting and corticosteroid.
  We emphasize that the worsening of tuberculous le-
sions may occur during antituberculosis chemotherapy 
even in case of the intestinal tuberculosis and does not 
necessarily indicate treatment failure. The combination of 
steroid therapy and biliary stenting can be an option in 
the treatment of obstructive jaundice by PR of periportal 
lymphadenitis.
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